SMStefan Müller-Hülsbeck

Stefan Müller-Hülsbeck

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stefan Müller-Hülsbeck has a total of 240 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Large Core Stroke Thrombectomy Is Safe and Effective Regardless of Prior Antithrombotic or Thrombolytic Treatment: A Secondary Analysis of the Randomized TENSION Trial

    by Eckhard Schlemm, Märit Jensen, Maximilian Schell, Jens Fiehler, Fabien Subtil, Susanne Bonekamp, Anne Hege Aamodt, Blanca Fuentes, Elke R. Gizewski, Michael D. Hill, et al.

    Background: The relevance of prior antithrombotic and thrombolytic treatment for decision‐making regarding endovascular thrombectomy (EVT) for acute ischemic stroke due to large vessel occlusion with established large infarcts is uncertain. This study investigates associations of prior antithrombotic medication and thrombolysis with the efficacy and safety of EVT for acute ischemic stroke due to large vessel occlusion with established large infarct. Methods: TENSION (Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window) was a prospective randomized open‐label blinded–end point clinical trial. Patients with acute ischemic stroke due to large vessel occlusion and established large infarct were randomized to EVT with medical therapy or medical therapy alone. Exposures were preadmission antithrombotic treatment with antiplatelet agents or anticoagulants and intravenous thrombolysis. The primary efficacy end point was functional outcome at 90 days. Safety outcomes included death and symptomatic intracranial hemorrhage. Results: The study included 246 patients (median age, 74 years; interquartile range, 65 to 80 years; 49% women); 124 (50%) were assigned to EVT. Of 176 patients (72%) with prior antithrombotic therapy, 75 (31%) received antiplatelets, 56 (23%) anticoagulants, and 89 (36%) intravenous thrombolysis. EVT was associated with better functional outcome in patients with (common odds ratio [cOR], 2.40 [95% CI, 1.22–4.99]) and without (cOR, 2.29 [95% CI, 1.53–3.46]) antiplatelet therapy; with (cOR, 2.45 [95% CI, 1.17–5.28]) and without (cOR, 2.12 [95% CI, 1.44–3.15]) anticoagulation; as well as receiving (cOR, 1.46 [95% CI, 0.83–2.61]) and not receiving (cOR, 2.89 [95% CI, 1.87–4.51]) thrombolysis. Interaction analyses were consistent with similar treatment effects across subgroups. Mortality and rates of symptomatic intracranial hemorrhage were similar between groups. Conclusions: Benefit and safety of EVT were not modified by prior antithrombotic/thrombolytic therapy. Preadmission exposure to antiplatelets or anticoagulants or use of intravenous thrombolysis should not exclude eligible patients with stroke from EVT. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03094715.

  • Open Access

    Is it prime time for carotid artery stenting in asymptomatic and symptomatic carotid artery stenosis?

    by Stefan Müller-Hülsbeck, Robert A. Morgan, Patrick Haage, Mohamad Hamady, Hicham Kobeiter, Romaric Loffroy, Florian Wolf, Gianpaolo Carrafielo, Matteo Stefanini

  • Open Access

    The ups and downs of paclitaxel-coated balloons and paclitaxel eluting stents: do the conclusions of SWEDEPAD 2 change our practice? Should we be concerned about mortality (again)?

    by Stefan Müller-Hülsbeck, Fabrizio Fanelli, Patrick Haage, Mohamad Hamady, Hicham Kobeiter, Romaric Loffroy, Gerard O’sUllivan, Lakshmi A. Ratnam, Catharina S. P. van Rijswijk, Maria Antonella Ruffino, et al.

    The use of paclitaxel-coated devices (PCDs) in peripheral arterial disease continues to generate interest and controversy. The PCD journey to date has been a story of highs and lows. The recently published SWEDEPAD 1 and 2 trials have rekindled discussion regarding efficacy and a potential link to mortality.


  • Open Access

    CIRSE Position Statement on Endovascular Aortic Repair

    by Mohamad Hamady, Catharina S. P. van Rijswijk, Hicham Kobeiter, Maria Antonella Ruffino, Fabrizio Fanelli, Patrick Haage, Romaric Loffroy, Stefan Müller-Hülsbeck, Gerard O’sullivan, Florian Wolf, et al.

  • Thrombectomy With Low ASPECTS: The Roles of Infarct Volume and Postacute Neurological Status

    by Helge Kniep, Susanne Gellißen, Götz Thomalla, Martin Bendszus, Laurens Winkelmeier, Gabriel Broocks, Matthias Bechstein, Fabien Subtil, Susanne Bonekamp, Anne Hege Aamodt, et al.

    BACKGROUND: Recent randomized trials demonstrated the beneficial effect of endovascular therapy in patients with low Alberta Stroke Program Early CT Score. Despite large follow-up infarct volumes, a significantly increased rate of good functional outcomes was observed, challenging the role of infarct volume as a predictive imaging marker. This analysis evaluates the extent to which the effects of endovascular thrombectomy on functional outcomes are explained by (1) follow-up infarct volume and (2) early neurological status in patients with stroke with low Alberta Stroke Program Early CT Score. METHODS: TENSION (Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window) was a randomized trial conducted from February 2018 to January 2023 across 41 stroke centers. Two hundred fifty-three patients with ischemic stroke due to anterior circulation large vessel occlusion and Alberta Stroke Program Early CT Score of 3 to 5 were randomized to endovascular thrombectomy plus medical treatment or medical treatment alone. All patients with the availability of relevant data points were included in this secondary as-treated analysis. The primary outcome was the 90-day modified Rankin Scale score. Confounder-adjusted mediation analysis was performed to quantify the proportion of the treatment effect on a 90-day modified Rankin Scale score explained by (1) 24-hour follow-up infarct volume and (2) 24-hour National Institutes of Health Stroke Scale scores. RESULTS: One hundred eighty-eight patients were included; thereof, 87 (46%) were female patients. Median age was 72 (interquartile range, 63–79) years. The endovascular thrombectomy cohort had a 20.5 (95% CI, 8.3–33.7) percentage points higher probability of achieving independent ambulation (modified Rankin Scale, 0–3) and a 24.2 (95% CI, 13.4–35.8) percentage points lower mortality at 90 days compared with medical treatment alone. The reduction in 24-hour follow-up infarct volume explained 30% of the treatment effect on functional outcomes, while the 24-hour National Institutes of Health Stroke Scale score explained 61%. CONCLUSIONS: In patients with low Alberta Stroke Program Early CT Score, infarct volume demonstrated limited explanatory power for functional outcomes compared with the early neurological status, which may more effectively reflect factors such as the involvement of specific brain regions, disruption of structural networks, and selective neuronal loss.


  • Open Access

    Contemporary carotid artery stenting practices and peri-procedural outcomes in different European countries: ROADSAVER study multicentric insights

    by Stefan Müller-Hülsbeck, Zsolt Vajda, Piotr Odrowąż-Pieniążek, Zoltán Ruzsa, Roel Beelen, Aleksandar Gjoreski, Koen Deloose, Sérgio Castro, Benjamin Faurie, Alejandro Tomasello Weitz, et al.

    Background: Regional variations in patient selection and procedural techniques for carotid artery stenting have been well documented. However, their impact on procedural outcomes, especially with the use of dual-layer micromesh stents, is not fully understood. Methods: This prospective, multi-center observational study included 1965 patients with asymptomatic or symptomatic carotid artery stenosis treated with the Roadsaver dual-layer micromesh stent. The primary outcome measure was the 30-day rate of major adverse events, defined as any death or stroke occurring within 30 days post-procedure. This sub-analysis compared patient characteristics and procedural techniques across 13 participating countries and investigated differences in outcomes via logistic regression modelling. Results: Patient demographics, comorbidities, and symptom presentation varied widely among countries. Similarly, the frequency of use of duplex ultrasound and diffusion-weighted magnetic resonance imaging at baseline and 30-day follow-up differed. Procedural approaches also varied, with differences in femoral access site selection (18.2% to 100.0%), use of embolic protection devices (0.0% to 100.0%), pre-dilatation (4.3% to 46.7%) and post-dilatation (66.7% to 100.0%). Although 30-day major adverse event rates differed across the compared countries, after adjusting for post-dilatation balloon pressure (categorized as no post-dilatation vs. ≤ 11atm vs. > 11atm), and the number of enrolled patients per study site, the difference became statistically non-significant. Conclusion: Our study reveals variability in patient selection, procedural carotid stenting practices and clinical outcomes across European countries. The differences in 30-day any death or stroke rates between countries may be attributed to differing post-dilatation practices and the number of enrolled patients per study site. Level of evidence: Level 3, observational study. Trial registration: Clinicaltrials.gov identifier: NCT03504228. Visual


  • Open Access

    30-Day Outcomes of Real-World Elective Carotid Stenosis Treatment Using a Dual-Layer Micromesh Stent (ROADSAVER Study)

    by Ralf Langhoff, Zsolt Vajda, Piotr Odrowąż-Pieniążek, Aleksandar Gjoreski, Roel Beelen, Koen Deloose, Balázs Nemes, Zoltán Ruzsa, Jean-Luc Banos, Sérgio Castro, et al.

    Purpose: Carotid artery stenting with single-layer stents carries a risk of periprocedural cerebral embolization compared to carotid endarterectomy. Dual-layer micromesh stents were designed for improved plaque coverage and sustained embolic protection. This analysis aimed to confirm the Roadsaver dual-layer micromesh stent safety in a real-world carotid artery stenting cohort. Materials and Methods: ROADSAVER was a prospective, single-arm, multicenter, observational study. Patients with carotid artery stenosis, eligible for elective stenting, were enrolled at 52 sites across 13 European countries. All procedures followed standard practice. The primary outcome was the 30-day major adverse event rate, defined as the cumulative incidence of any death or stroke. All deaths, strokes, and carotid artery revascularizations were independently adjudicated. Results: In total, 1965 patients were analysed (mean age 70.6 ± 8.8 years). Cerebral ischaemia symptoms were present in 49.4% of participants. Radial/ulnar access was used in 26.3% of cases and embolic protection in 63.8%. The 30-day major adverse event incidence was 2.2% (1.6% in asymptomatic and 2.8% in symptomatic patients), with any stroke at 1.9%, any death at 0.8%, and stroke-related death at 0.5%. Predictors of higher 30-day major adverse event risk, identified through multivariable modelling, included residual stenosis ≥ 30%, thromboembolic venous disease, previous myocardial infarction, age ≥ 75 years, family history of atherosclerosis, non-insulin-dependent diabetes mellitus, symptomatic carotid stenosis, and stent length. Conclusion: Dual-layer micromesh carotid artery stenting is safe, with a low 30-day major adverse event incidence in real-world asymptomatic and symptomatic patients, supporting the sustained embolic protection design concept. Level of Evidence: Level 2, observational study (with dramatic effect). Graphical


  • Open Access

    The Central Role of the Interventional Radiologist in Advanced Therapies for Pulmonary Embolism: Results from An Online Member Survey by the Cardiovascular and Interventional Radiological Society of Europe

    by Gerard O’sullivan, Stefan Müller-Hülsbeck, Patrick Haage, Florian Wolf, Mohamad Hamady, Birgit Slijepčević, Romaric Loffroy, Fabrizio Fanelli, Hicham Kobeiter, Robert A. Morgan

    Purpose: To describe the outcomes of a survey on the provision of interventional radiology procedures for the treatment of acute pulmonary embolism (PE) in Europe and beyond. Methods: An online survey with 14 structured items was designed by the authors and was sent to 7116 CIRSE members via email. The anonymous online survey collected data for eight weeks; only complete responses were statistically analysed. Results: The survey was completed by 373 members (5.24%). Among these, 75.1% worked at centres offering catheter-directed thrombolysis or thrombectomy, in which 89.3% (250) personally perform endovascular treatment techniques for pulmonary embolism and the IR department is primarily responsible for the endovascular treatment techniques of PE in 83.2% of cases. The most frequently used endovascular techniques were (large bore) aspiration thrombectomy (85%) and catheter-directed thrombolysis (58.9%). The most common indications for intervention were sub-massive and massive PE (69.9%) and massive PE only (28%). In 70% of centres offering catheter-directed thrombolysis or thrombectomy, three or more Interventional Radiologists (IRs) are involved in PE treatment. Multidisciplinary rapid response teams for PE were available in 40.8% of centres, and included IRs in 91.4%. Conclusion: IRs are heavily involved in the management of patients with massive and sub-massive pulmonary embolism; further research is mandated to address clinical questions including patient selection and the timing for transcatheter therapies of PE provided by IR. Graphical


  • Open Access

    Interventional Radiologists Must be Involved in the Management of Patients with Massive and Sub-massive Pulmonary Embolism

    by Gerard O’sUllivan, Stefan Müller-Hülsbeck, Patrick Haage, Florian Wolf, Mohamad Hamady, Romaric Loffroy, Fabrizio Fanelli, Hicham Kobeiter, Robert A. Morgan